Black Diamond Therapeutics Inc Aktie News

CAMBRIDGE, Mass., 10. Nov. 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), ein im klinischen Stadium tätiges Onkologieunternehmen, das MasterKey‑Therapien entwickelt, die Familien onkogener Mutationen bei Krebspatienten adressieren, darunter silevertinib, ein potenziell best‑in‑class gehirnpenetrantes Inhibitor des epidermalen Wachstumsfaktorrezeptors (EGFR), berichtet...

CAMBRIDGE, Mass., 05. Aug. 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), ein im klinischen Stadium befindliches Onkologieunternehmen, das MasterKey-Therapien entwickelt, die Familien von onkogenen Mutationen bei Krebspatienten ansprechen, einschließlich silevertinib, einem potenziell best-in-class gehirndurchdringenden Inhibitor des epidermalen Wachstumsfaktor-Rezept...

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on J...

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor ...

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.